Research Project

Project Title:	MONET STUDY
Project Type:	Clinical Trial, Enrolment ongoing
Disease group(s):	Immune glomerulopathies
Project Summary:	This is an open-label, phase II study in which all participants will receive active treatment with MOR202 (felzartamab), for a total of nine doses during 24 weeks. Patients will be monitored up to month 24 from the first treatment.
Lead principal investigator(s):	Piero Ruggenenti, Bergamo
Co-investigator(s):	, Matias Trillini, Bergamo
Project Period:	12/2021 - 12/2024
EudraCT Nr.:	2021-000835-30